Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 10/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17113535 | 0.89 | IRAK4 (0.39) | IRAK4LPLLIPGIDO1TDO2 | |
| SCHEMBL24873712 | 0.88 | LPL (0.40) | IRAK4LPLLIPGIDO1TDO2 | |
| SCHEMBL25322666 | 0.83 | MAPT (0.37) | IRAK4LPLLIPGIDO1TDO2 | |
| Acetic Acid SCHEMBL25322169 | 0.81 | IDO1 (0.37) | IRAK4LPLLIPGIDO1TDO2 | |
| SCHEMBL5137400 | 0.81 | MAPT (0.49) | IRAK4LPLLIPGIDO1TDO2 | |
| Acetic Acid SCHEMBL25322175 | 0.80 | IDO1 (0.35) | IRAK4LPLLIPGIDO1TDO2 | |
| SCHEMBL5076707 | 0.78 | LPL (0.41) | IRAK4LPLLIPGIDO1TDO2 | |
| SCHEMBL31752127 | 0.77 | IDO1 (0.39) | IRAK4LPLLIPGIDO1TDO2 | |
| SCHEMBL5074870 | 0.77 | MEN1 (0.51) | IRAK4LPLLIPGIDO1TDO2 | |
| SCHEMBL22041263 | 0.76 | LPL (0.39) | IRAK4LPLLIPGIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2020055192-A2 | PREPARATION METHOD FOR QUINOLINE-5, 8-DIONE DERIVATIVE WHICH IS TGASE 2 INHIBITOR | 재단법인 대구경북첨단의료산업진흥재단 | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | IRAK4 4158/4885LPL 3972/4885LIPG 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.